Brief: Longboard Pharmaceuticals To Initiate Global Phase 3 Program Later This Year
01/07/2024 15:09
July 1 (Reuters) - Longboard Pharmaceuticals Inc
LBPH.O :
* LONGBOARD PHARMACEUTICALS RECEIVES BREAKTHROUGH THERAPY
DESIGNATION FOR BEXICASERIN (LP352)
* LONGBOARD PHARMACEUTICALS INC - TO INITIATE GLOBAL PHASE 3
PROGRAM LATER THIS YEAR
Source text for Eikon: ID:nBwlSf60a
Further company coverage: LBPH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Longboard Pharmaceuticals
See all newsBrief: Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin In Developmental And Epileptic Encephalopathies (DEEs)
Longboard Pharmaceuticals Inc expected to post a loss of 62 cents a share - Earnings Preview
Brief: Longboard Pharmaceuticals Under Agreement H Lundbeck Required To Pay Co Reverse Termination Fee Of $158.9 Mln In Cash
U.S. RESEARCH ROUNDUP- Cadence Design Systems, Equity Bancshares, S&P Global
Deals of the day-Mergers and acquisitions